These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO]. Ohlmann CH; Gschwend J; Miller K Urologe A; 2016 Sep; 55(9):1164-72. PubMed ID: 27431813 [TBL] [Abstract][Full Text] [Related]
46. The economics of abiraterone acetate for castration-resistant prostate cancer. Dellis A; Papatsoris AG Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):175-9. PubMed ID: 24564607 [TBL] [Abstract][Full Text] [Related]
47. Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study. Takahashi M; Kawabata R; Kawano A; Murakami Y; Sutou Y; Inai T; Akazawa S; Hamao T; Hayashi H; Fukawa T; Takemura M; Yamamoto Y; Yamaguchi K; Izaki H; Fukumori T; Kanayama H Int J Oncol; 2013 Sep; 43(3):713-20. PubMed ID: 23817692 [TBL] [Abstract][Full Text] [Related]
48. [Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]]. Rexer H Urologe A; 2014 Nov; 53(11):1665-7. PubMed ID: 25297491 [No Abstract] [Full Text] [Related]
49. Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs? Liaw BC; Oh WK Nat Rev Clin Oncol; 2015 Jun; 12(6):316-8. PubMed ID: 25917253 [No Abstract] [Full Text] [Related]
50. [Not Available]. Wolff JM Oncol Res Treat; 2017; 40 Suppl 2():11-12. PubMed ID: 28365709 [TBL] [Abstract][Full Text] [Related]
51. One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients? Loriot Y; Massard C; Fizazi K Eur Urol; 2014 Oct; 66(4):653-4. PubMed ID: 24735730 [No Abstract] [Full Text] [Related]
57. New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer. Heidegger I; Heidenreich A; Pfister D Target Oncol; 2017 Feb; 12(1):37-45. PubMed ID: 27796762 [TBL] [Abstract][Full Text] [Related]
58. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. Aziz A; Kempkensteffen C; May M; Lebentrau S; Burger M; Chun FK; Brookman-May S Expert Rev Anticancer Ther; 2015 Jun; 15(6):649-66. PubMed ID: 25905802 [TBL] [Abstract][Full Text] [Related]
59. The MAINSAIL trial: an expected failure. Boccardo F Lancet Oncol; 2015 Apr; 16(4):355-6. PubMed ID: 25743936 [No Abstract] [Full Text] [Related]
60. Ongoing Clinical Trials in Prostate Cancer: The STAMPEDE Trial. Oncol Res Treat; 2016; 39(7-8):464-7. PubMed ID: 27487186 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]